Boston Scientific (NYSE:BSX) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Boston Scientific (NYSE:BSX – Get Rating) in a research report released on Thursday morning. The firm issued a buy rating on the medical equipment provider’s stock.

A number of other research firms have also recently weighed in on BSX. Mizuho initiated coverage on Boston Scientific in a research note on Thursday, December 22nd. They issued a neutral rating and a $52.00 price target on the stock. Needham & Company LLC increased their price target on Boston Scientific from $48.00 to $53.00 and gave the company a buy rating in a research note on Thursday, February 2nd. TheStreet cut Boston Scientific from a b- rating to a c rating in a research note on Monday, November 28th. JPMorgan Chase & Co. increased their price target on Boston Scientific from $48.00 to $55.00 and gave the company an overweight rating in a research note on Thursday, February 2nd. Finally, Stifel Nicolaus upped their price objective on Boston Scientific from $50.00 to $52.00 in a report on Wednesday, February 1st. One equities research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Boston Scientific currently has an average rating of Buy and an average target price of $51.50.

Boston Scientific Trading Down 0.7 %

Shares of Boston Scientific stock opened at $47.95 on Thursday. Boston Scientific has a 12-month low of $34.98 and a 12-month high of $48.87. The stock has a market cap of $68.80 billion, a P/E ratio of 106.56, a P/E/G ratio of 2.26 and a beta of 0.79. The company has a quick ratio of 1.02, a current ratio of 1.51 and a debt-to-equity ratio of 0.51. The business’s 50 day moving average is $46.86 and its 200-day moving average is $44.24.

Boston Scientific (NYSE:BSX – Get Rating) last announced its quarterly earnings data on Wednesday, February 1st. The medical equipment provider reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.02). Boston Scientific had a return on equity of 14.29% and a net margin of 5.50%. The company had revenue of $3.24 billion for the quarter, compared to the consensus estimate of $3.24 billion. During the same quarter in the prior year, the company earned $0.45 EPS. The company’s revenue for the quarter was up 3.7% on a year-over-year basis. Equities research analysts predict that Boston Scientific will post 1.9 earnings per share for the current fiscal year.

Insider Transactions at Boston Scientific

In related news, CAO Jonathan Monson sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $46.66, for a total transaction of $233,300.00. Following the completion of the sale, the chief accounting officer now owns 34,868 shares of the company’s stock, valued at $1,626,940.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CAO Jonathan Monson sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $46.66, for a total transaction of $233,300.00. Following the completion of the sale, the chief accounting officer now owns 34,868 shares in the company, valued at $1,626,940.88. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Daniel J. Brennan sold 7,572 shares of the business’s stock in a transaction that occurred on Wednesday, February 15th. The shares were sold at an average price of $47.14, for a total value of $356,944.08. Following the sale, the chief financial officer now owns 276,316 shares of the company’s stock, valued at approximately $13,025,536.24. The disclosure for this sale can be found here. Insiders sold 115,182 shares of company stock worth $5,432,674 over the last ninety days. 0.71% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Montag A & Associates Inc. lifted its holdings in Boston Scientific by 8.5% during the 4th quarter. Montag A & Associates Inc. now owns 2,712 shares of the medical equipment provider’s stock worth $125,000 after purchasing an additional 212 shares in the last quarter. Childress Capital Advisors LLC grew its position in Boston Scientific by 3.5% during the 4th quarter. Childress Capital Advisors LLC now owns 6,201 shares of the medical equipment provider’s stock worth $287,000 after acquiring an additional 212 shares during the last quarter. Hazlett Burt & Watson Inc. grew its position in Boston Scientific by 56.7% during the 4th quarter. Hazlett Burt & Watson Inc. now owns 636 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 230 shares during the last quarter. Zions Bancorporation N.A. lifted its holdings in Boston Scientific by 14.8% in the 4th quarter. Zions Bancorporation N.A. now owns 1,793 shares of the medical equipment provider’s stock worth $83,000 after buying an additional 231 shares during the period. Finally, Vestcor Inc lifted its stake in shares of Boston Scientific by 0.8% in the 4th quarter. Vestcor Inc now owns 33,955 shares of the medical equipment provider’s stock valued at $1,571,000 after purchasing an additional 278 shares during the period. Hedge funds and other institutional investors own 90.23% of the company’s stock.

Boston Scientific Company Profile

(Get Rating)

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Urology and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions.